Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance

British Journal of Haematology

Volumn 127, Issue 3, 2004, Pages 308-310

  Rajkumar, S Vincent ^a,b   Kyle, Robert A ^a   Therneau, Terry M ^a   Clark, Raynell J ^b   Bradwell, Arthur R ^c,d   Melton III, L Joseph ^a   Larson, Dirk R ^a   Plevak, Matthew F ^a   Katzmann, Jerry A ^b  

^a Department of Health Sciences Research   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Binding Site Group Ltd   (United Kingdom)

Author keywords

Kappa light chains; Kappa lambda free light chain ratio; Lambda light chains; Monoclonal gammopathy of undetermined significance; Progression

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN;

ARTICLE; CLINICAL ARTICLE; CLONE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PRECANCER; PRIORITY JOURNAL; RISK FACTOR;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; PARAPROTEINEMIAS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 7944231889     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05169.x     Document Type: Article

References (11)

1. Abraham, R.S., Clark, R.J., Bryant, S.C., Lymp, J.F., Larson, T., Kyle, R.A. & Katzmann, J.A. (2002) Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clinical Chemistry, 48, 655-657.
2. Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Harvey, T.C. & Drayson, M.T. (2003) Serum test for assessment of patients with Bence Jones myeloma. Lancet, 361, 489-491.
3. Cesana, C., Klersy, C., Barbarano, L., Nosari, A.M., Crugnola, M., Pungolino, E., Gargantini, L., Granata, S., Valentini, M. & Morra, E. (2002) Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Journal of Clinical Oncology, 20, 1625-1634.
4. Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H. & Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretoiy multiple myeloma. Blood, 97, 2900-2902.
5. Katzmann, J.A., Clark, R.J., Abraham, R.S., Bryant, S., Lymp, J.F., Bradwell, A.R. & Kyle, R.A. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48, 1437-1444.
6. Kyle, R.A. (1993) 'Benign' monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clinic Proceedings, 68, 26-36.
7. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. III (2002) A long-term study of prognosis of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564-569.
8. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. III (2003a) Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among Olmsted County, MN Residents 50 years of age. Blood, 102, 934a (A3476).
9. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Remstein, E.D., Offord, J.R., Larson, D.R., Plevak, M.F. & Melton, L.J. I (2003b) Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood, 102, 3759-3764.
10. Lachmann, H.J., Gallimore, R., Gillmore, J.D., Carr-Smith, H.D., Bradwell, A.R., Pepys, M.B. & Hawkins, P.N. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology, 122, 78-84.
11. Rajkumar, S.V., Mesa, R.A., Fonseca, R., Schroeder, G., Plevak, M.F., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Gertz, M.A., Kyle, R.A., Russell, S.J. & Greipp, P.R. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clinical Cancer Research, 8, 2210-2216.